Trial Profile

A Phase 1b, Randomized, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) and Interferon Gamma (IFN-gamma) for Recurrent Glioblastoma or Gliosarcoma (TARGET-I)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 06 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tasadenoturev (Primary) ; Interferon gamma
Indications Glioblastoma; Gliosarcoma
Focus Therapeutic Use
Acronyms TARGET-I
Sponsors DNAtrix

Most Recent Events

23 Sep 2023 Results assessing the impact of neutralizing antibodies developed in patients during a phase 1 clinical trial of Delta-24-RGD for the treatment of recurrent malignant gliomas, presented at the CRI-ENCI-AACR: 7th Annual International Cancer, Immunotherapy Conference.
12 Jul 2018 Status changed from active, no longer recruiting to completed.
30 Jan 2018 Planned primary completion date changed from 1 Aug 2017 to 15 Mar 2018.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com